跳到正文
原文
MedPage Today·· 2026-10-09精选AI 评分85

FDA 批准阿替利珠单抗联合化疗用于 III 期 dMMR 结肠癌辅助治疗

FDA Approves Adjuvant Atezolizumab for Certain Colon Cancers

AI 导读

FDA 批准静脉注射阿替利珠单抗(Tecentriq)联合氟尿嘧啶类和奥沙利铂,用于 2 岁及以上 III 期错配修复缺陷(dMMR)结肠癌的辅助治疗,同时批准其皮下制剂(阿替利珠单抗加透明质酸酶,Tecentriq Hybreza)用于 12 岁及以上、体重至少 88 磅的患者。

推荐理由

FDA 依据 ATOMIC 试验批准该辅助治疗适应症,3 年无病生存率 86% 对 76% 可供对照参考。

正文

— Immunotherapy lands indication in combination with chemo for stage III dMMR tumors

October 9, 2026 • 2 min read

The FDA on Thursday approved intravenous atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III mismatch repair-deficient (dMMR) colon cancer in patients 2 years and up.

The agency also approved the subcutaneous form of the PD-L1 inhibitor (atezolizumab plus hyaluronidase [Tecentriq Hybreza]) for the indication in patients 12 years and older who weigh at least 88 lb.

In the randomized trial supporting these approvals, the addition of atezolizumab to standard adjuvant chemotherapy reduced the risk of disease recurrence or death by 50%.

"Until now, the adjuvant standard of care for stage III colon cancer has not differed based on mismatch repair status," said Frank Sinicrope, MD, of the Mayo Clinic in Rochester, Minnesota, who was a principal investigator for the trial, in a press release from drugmaker Genentech.

"This milestone represents an important therapeutic advance that leverages immunotherapy to target the specific biology of dMMR stage III colon cancer after surgical resection," he noted. "By reducing the risk of disease recurrence or death by 50%, atezolizumab plus chemotherapy is a practice-changing regimen that can improve clinical outcomes of this group of patients living with colon cancer, one of the most common cancers and a leading cause of cancer-related death."

Efficacy was evaluated in ATOMIC/ML39057, a multicenter, open-label trial, which included 711 patients with stage III dMMR colon cancer who were randomized to receive either atezolizumab in combination with oxaliplatin, leucovorin, and fluorouracil for 12 cycles followed by atezolizumab monotherapy for 6 months, or the chemotherapy regimen alone for 12 cycles.

The 3-year disease-free survival rate was 86% with the addition of atezolizumab compared with 76% for those who received chemotherapy alone (HR 0.50, 95% CI 0.35-0.73, P<0.0001).

An analysis of patients with dMMR cancer confirmed by central laboratory review yielded an HR of 0.53 (95% CI 0.36-0.79, P=0.0007).

Grade ≥3 adverse events occurred more often in the atezolizumab arm (71.7% vs 62.1%), but the safety profile of atezolizumab plus chemotherapy was consistent with the drugs' known effects.

The prescribing information includes warnings and precautions for immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic hematopoietic stem-cell transplantation, and embryo-fetal toxicity.

来源:MedPage Today · medpagetoday.com